Uric acid, allopurinol therapy, and mortality in patients with acute heart failure-results of the Acute HEart FAilure Database registry

Journal of Critical Care

Volumn 27, Issue 6, 2012, Pages 737.e11-737.e24

  Málek, Filip ^a   Ošťádal, Petr ^a   Pařenica, Jiří ^b   Jarkovský, Jiří ^c   Vítovec, Jiří ^d   Widimský, Petr ^e   Linhart, Aleš ^f   Fedorco, Marián ^g   Coufal, Zdeněk ^h   Miklík, Roman ^b   Kruger, Andreas ^a   Vondraková, Dagmar ^a   Špinar, Jindřich ^b  

^a NA HOMOLCE HOSPITAL   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

^d ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

^f CHARLES UNIVERSITY   (Czech Republic)

^g UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^h Krajska Nemocnice T Bati as   (Czech Republic)

Author keywords

Acute heart failure; Allopurinol; Mortality; Uric acid

Indexed keywords

ALLOPURINOL; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; HEMOGLOBIN; URIC ACID;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CARDIOGENIC SHOCK; COHORT ANALYSIS; CONTROLLED STUDY; CZECH REPUBLIC; DE NOVO HEART FAILURE; DISEASE REGISTRY; FEMALE; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; URIC ACID BLOOD LEVEL;

EID: 84870707337     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2012.03.011     Document Type: Article

References (24)

1. Anker S.D., Doehner W., Rauchaus M., et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003, 107:1991-1997.
2. Jankowska E.A., Ponikowska B., Majda J., et al. Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. Int J Cardiol 2007, 115:151-155.
3. Filipatos G.S., Ahmed M.I., Gladden J.D., et al. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J 2011, 32:712-720.
4. Tamariz L., Harzand A., Palacio A., et al. Uric acid as a predictor of all-cause mortality in heart failure: a meta analysis. Congest Heart Fail 2011, 17:25-30.
5. Levya F., Anker S.D., Godsland I.F., et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998, 19:1814-1822.
6. Hare J.M., Johnson R.J. Uric acid predicts clinical outcomes in heart failure: insight regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation 2003, 107:1951-1953.
7. Doehner W., von Haehling S., Anker S.D. Uric acid in CHF: marker or player in a metabolic disease?. Int J Cardiol 2007, 115:156-158.
8. Hare J.M., Mangal B., Brown J. Impact of oxypurinol in patients with symptomatic heart failure: results of the OPT-CHF study. JACC 2008, 24(51):2301-2309.
9. Doehner W., von Haehling S., Anker S.D. Uric acid as a prognostic marker in acute heart failure-new expectations from an old molecule. Eur J Heart Fail 2007, 9:437-439.
10. Pascual Figal D.A., Hurtado-Martínez J.A., Redondo B., et al. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail 2007, 9:518-524.
11. Cockroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
12. Levya F., Anker S., Swan J.W., et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997, 18:858-865.
13. Bettencourt P., Ferreira A., Dias P., et al. Predictors of prognosis in patients with stable mild to moderate heart failure. J Card Fail 2000, 6:306-313.
14. Batin P., Wickens M., McEntegart D., et al. The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur Heart J 1995, 16:1613-1618.
15. Wei L., Fandy A., Struthers A.D., MacDonald T.M. Association between allopurinol and mortality in heart failure patients: a long-term follow-up study. Int J Clin Pract 2009, 63(9):1327-1333.
16. Engberding N., Spiekermann S., Schaefer A., et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction. A new action for an old drug?. Circulation 2004, 110:2175-2179.
17. Mellin V., Isabelle M., Oudot A., et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J 2005, 26:1544-1550.
18. 2+ cycling and β-adrenergic hyporesponsiveness in heart failure. Am J Physiol Heart Circ Physiol 2007, 292:H1328-H1335.
19. Farquharson C.A.J., Hitler R., Hill A., et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002, 106:221-226.
20. Georgie J., Carr E., Davies J., et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006, 114:2508-2516.
21. Ogino K., Kato M., Furuse Y., et al. Uric-acid lowering treatment with benzbromarone in patients with heart failure. Circ Heart Fail 2010, 3:73-81.
22. Dobson A. Is raised serum uric acid a cause of cardiovascular disease or death?. Lancet 1999, 354:1578.
23. Engberding N., Spiekermann S., Schaefer A., et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction-a new action for an old drug?. Circulation 2004, 110:2175-2179.
24. Kittleson M.M., St John M.E., Bead V., et al. Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels. Heart 2007, 93:365-367.